Julie Louise Gerberding is Chief patient officer and executive vice president, Population Health & Sustainability at Merck.
As chief patient officer and executive vice president, Population Health & Sustainability, Dr. Julie Gerberding is responsible for patient engagement, corporate social responsibility, ESG and other functions. Formerly, Dr. Gerberding oversaw Global Public Policy and Strategic Communications for the company. She joined Merck in 2010 as president of vaccines and was instrumental in increasing access to the company’s vaccines to people around the world.
Previously, Dr. Gerberding was Director of the U.S. CDC, where she led the agency through SARS and over 40 emergency responses to public health crises. She serves on the Boards of Cerner Corporation and MSD Wellcome Trust Hilleman Laboratories, a non-profit that develops new technologies for developing countries. She also co-chairs the CSIS Commission on Strengthening America’s Health Security.
Dr. Gerberding received her undergraduate and M.D. degrees from Case Western Reserve University and a Masters of Public Health at the University of California, Berkeley. She completed her internship and residency in Internal Medicine and fellowship in Clinical Pharmacology and Infectious Diseases at the University of California, San Francisco, where she is currently an Adjunct Associate Professor of Medicine.